VectivBio Holding AG (VECT) Stock Analysis

What VectivBio Holding AG does

VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.

Key metrics

ETFs linked to VECT

Broad-market and Healthcare sector ETFs an investor holding VectivBio Holding AG is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VECT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for VectivBio Holding AG?

VectivBio Holding AG trades under the ticker VECT on NASDAQ.

Which exchange is VECT listed on?

VECT is listed on NASDAQ.

What sector does VectivBio Holding AG operate in?

VectivBio Holding AG is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze VECT in a portfolio?

PortView shows VECT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.